Uso de recubrimientos protésicos de plata en cirugía tumoral: influencia en la tasa de infección

Andrés Aguilar Ezquerra; Antonio Peguero Bona

doi:10.31053/1853.0605.v74.n3.14892

Authors

Andrés Aguilar Ezquerra Hospital universitario Miguel Servet
Antonio Peguero Bona Hospital Miguel Servet

DOI:

https://doi.org/10.31053/1853.0605.v74.n3.14892

Keywords:

silver coating, megaprostheses, infection.

Abstract

Introduction: megaprostheses are one of the most widely used treatments in oncological surgery, and one of its major complications is the high rate of infection. Methods: 30 patients underwent implantation of silver-coated Mutars® arthroplasty due to neoplastic disease or periprosthetic fracture. Clinical and analytical monitoring was performed with a minimum of 4 years follow-up. Results: During follow-up 3 infections (10% of patients) were detected, less than publications using non silver-coated prostheses. Conclusion: silver coating in megaprostheses seems to decrease infection rate.

Author Biography

Andrés Aguilar Ezquerra, Hospital universitario Miguel Servet

Médico especialista en Cirugía Ortopédica y Traumatología.
Doctor en Cirugía Ortopédica y Traumatología por la universidad de Zaragoza.

References

1.- Gkavardina A1, Tsagozis P1. The use of megaprostheses for reconstruction of large skeletal defects in the extremities: a critical review. Open Orthop J. 2014 Oct 17; 8:384-9.

2.- Tsagkozis P, Brosjö O, Bauer HC. Reconstruction with modular megaprostheses for sarcomas of the lower extremity. Orthopedics. 2015 May;38(5):e401-6.

3.-Ham SJ1, Schraffordt Koops H, Veth RP, van Horn JR, Molenaar WM, Hoekstra HJ. Limb salvage surgery for primary bone sarcoma of the lower extremities: long-term consequences of endoprosthetic reconstructions. Ann Surg Oncol. 1998 Jul-Aug;5(5):423-36.

4.- Mittermayer F1, Krepler P, Dominkus M, Schwameis E, Sluga M, Heinzl H, et al. Long-term followup of uncemented tumor endoprostheses for the lower extremity. Clin Orthop Relat Res. 2001 Jul;(388):167-77.

5.- Capanna R1, Morris HG, Campanacci D, Del Ben M, Campanacci M. Modular uncemented prosthetic reconstruction after resection of tumours of the distal femur. J Bone Joint Surg Br. 1994 Mar;76(2):178-86.

6.- Gosheger G1, Goetze C, Hardes J, Joosten U, Winkelmann W, von Eiff C. The influence of the alloy of megaprostheses on infection rate. J Arthroplasty. 2008 Sep;23(6):916-20.

7.- Pilge H1, Gradl G, von Eisenhart-Rothe R, Gollwitzer H. Incidence and outcome after infection of megaprostheses. Hip Int. 2012 Jul-Aug;22 Suppl 8:S83-90.

8.- Hardes J1, Ahrens H, Gosheger G, Nottrott M, Dieckmann R, Henrichs MP, et al. Management of complications in megaprostheses. Unfallchirurg. 2014 Jul;117(7):607-13.

9.- Hardes J1, Ahrens H, Gebert C, Streitbuerger A, Buerger H, Erren M, et al. Lack of toxicological side-effects in silver-coated megaprostheses in humans.Biomaterials. 2007 Jun;28(18):2869-75.

10.- Glehr M1, Leithner A, Friesenbichler J, Goessler W, Avian A, Andreou D, et al. Argyria following the use of silver-coated megaprostheses: no association between the development of local argyria and elevated silver levels. Bone Joint J. 2013 Jul;95-B(7):988-92.

11.- Ewald A1, Glückermann SK, Thull R, Gbureck U. Antimicrobial titanium/silver PVD coatings on titanium. Biomed Eng Online. 2006 Mar 24;5:22.

12.- Hussmann B1, Johann I, Kauther MD, Landgraeber S, Jäger M, Lendemans S. Measurement of the silver ion concentration in wound fluids after implantation of silver-coated megaprostheses: correlation with the clinical outcome. Biomed Res Int.2013:763096.

13.-Hardes J1, Streitburger A, Ahrens H, Nusselt T, Gebert C, Winkelmann W, et al. The influence of elementary silver versus titanium on osteoblasts behaviour in vitro using human osteosarcoma cell lines. Sarcoma.2007:26539.

14.- Gosheger G, Hillmann A, Lindner N, Rödl R, Hoffmann C, Bürger H, et al. Soft tissue reconstruction of megaprostheses using a Trevira tube. . Clin Orthop Relat Res. 2001;(393):264-71.

15.- Pala E1, Trovarelli G, Calabrò T, Angelini A, Abati CN, Ruggieri P. Survival of modern knee tumor megaprostheses: failures, functional results, and a comparative statistical analysis. Clin Orthop Relat Res. 2015 Mar;473(3):891-9.

16.- Capanna R1, Scoccianti G, Frenos F, Vilardi A, Beltrami G, Campanacci DA. What was the survival of megaprostheses in lower limb reconstructions after tumor resections? Clin Orthop Relat Res. 2015 Mar;473(3):820-30.

17.-Gosheger G1, Hardes J, Ahrens H, Streitburger A, Buerger H, Erren M, et al. Silver-coated megaendoprostheses in a rabbit model--an analysis of the infection rate and toxicological side effects. Biomaterials. 2004 Nov;25(24):5547-56.

18.- Heisel C1, Breusch SJ, Schmid G, Bernd L. Lower limb salvage surgery with MUTARS endoprostheses: 2 to 7 year results. Acta Orthop Belg. 2004 Apr;70(2):142-7.

19.- Gosheger G1, Gebert C, Ahrens H, Streitbuerger A, Winkelmann W, Hardes J. Endoprosthetic reconstruction in 250 patients with sarcoma Clin Orthop Relat Res. 2006 Sep;450:164-71.

20.- Hardes J1, von Eiff C, Streitbuerger A, Balke M, Budny T, Henrichs MP, et al. Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol. 2010 Apr 1;101(5):389-95.

21.- Wafa, H; Grimer, R J; Reddy, K; Jeys, L; Abudu, A; Carter, S R; et al. Retrospective evaluation of the incidence of early periprosthetic infection with silver-treated endoprostheses in high-risk patients: case-control study. Bone Joint J 2015;97-B:252-7.

22.- Ghani Y1, Coathup MJ, Hing KA, Blunn GW. Development of a hydroxyapatite coating containing silver for the prevention of peri-prosthetic infection. J Orthop Res. 2012 Mar;30(3):356-63.